WO1996032963A9 - Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins - Google Patents
Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteinsInfo
- Publication number
- WO1996032963A9 WO1996032963A9 PCT/US1996/005226 US9605226W WO9632963A9 WO 1996032963 A9 WO1996032963 A9 WO 1996032963A9 US 9605226 W US9605226 W US 9605226W WO 9632963 A9 WO9632963 A9 WO 9632963A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- lipoprotein
- lipo
- cell
- dex
- Prior art date
Links
- 102000004895 Lipoproteins Human genes 0.000 title claims abstract description 85
- 108090001030 Lipoproteins Proteins 0.000 title claims abstract description 85
- 150000004676 glycans Polymers 0.000 title claims abstract description 51
- 229920001282 polysaccharide Polymers 0.000 title claims abstract description 51
- 239000005017 polysaccharide Substances 0.000 title claims abstract description 51
- 150000004804 polysaccharides Polymers 0.000 title claims abstract description 51
- 230000001939 inductive effect Effects 0.000 title abstract description 23
- 230000001580 bacterial Effects 0.000 title abstract description 15
- 230000028993 immune response Effects 0.000 title abstract description 15
- 229960005486 vaccines Drugs 0.000 claims description 21
- 241000606768 Haemophilus influenzae Species 0.000 claims description 8
- 230000004913 activation Effects 0.000 claims description 8
- 229940045808 Haemophilus influenzae type b Drugs 0.000 claims description 6
- 241000607142 Salmonella Species 0.000 claims description 4
- 206010039447 Salmonellosis Diseases 0.000 claims description 4
- 241000193998 Streptococcus pneumoniae Species 0.000 claims description 4
- 241000193990 Streptococcus sp. 'group B' Species 0.000 claims description 4
- 241000588650 Neisseria meningitidis Species 0.000 claims description 3
- 239000000427 antigen Substances 0.000 abstract description 43
- 102000038129 antigens Human genes 0.000 abstract description 43
- 108091007172 antigens Proteins 0.000 abstract description 43
- 230000002708 enhancing Effects 0.000 abstract description 15
- 210000004027 cells Anatomy 0.000 description 70
- 230000004044 response Effects 0.000 description 44
- 230000028327 secretion Effects 0.000 description 43
- 210000003719 B-Lymphocytes Anatomy 0.000 description 38
- 241000700159 Rattus Species 0.000 description 29
- 102000004965 antibodies Human genes 0.000 description 19
- 108090001123 antibodies Proteins 0.000 description 19
- 102000004854 Immunoglobulin M Human genes 0.000 description 15
- 230000035755 proliferation Effects 0.000 description 15
- 230000000284 resting Effects 0.000 description 15
- 229960000814 tetanus toxoid Drugs 0.000 description 14
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004127 Cytokines Human genes 0.000 description 11
- 108090000695 Cytokines Proteins 0.000 description 11
- 210000002966 Serum Anatomy 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000002158 endotoxin Substances 0.000 description 9
- 230000001404 mediated Effects 0.000 description 9
- 108060007869 BAH1 Proteins 0.000 description 8
- 102100019937 DHRS2 Human genes 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 102100018758 IL3 Human genes 0.000 description 7
- 108010002386 Interleukin-3 Proteins 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 108010002616 Interleukin-5 Proteins 0.000 description 7
- 230000001419 dependent Effects 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000004369 Blood Anatomy 0.000 description 6
- 101700086956 IFNG Proteins 0.000 description 6
- 102100016020 IFNG Human genes 0.000 description 6
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 102100006400 CSF2 Human genes 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 5
- 210000001744 T-Lymphocytes Anatomy 0.000 description 5
- 238000004166 bioassay Methods 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 230000004940 costimulation Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N Resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 230000000240 adjuvant Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000001808 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 230000004727 humoral immunity Effects 0.000 description 4
- 230000003248 secreting Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 3
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 3
- 206010003997 Bacteraemia Diseases 0.000 description 3
- 210000002421 Cell Wall Anatomy 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- -1 IgG3 Proteins 0.000 description 3
- 108010002352 Interleukin-1 Proteins 0.000 description 3
- 101700036078 Miga Proteins 0.000 description 3
- 210000000952 Spleen Anatomy 0.000 description 3
- 108010092993 anti-IgD Proteins 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000000813 microbial Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- UCSJYZPVAKXKNQ-HZYVHMACSA-N 1-[(1S,2R,3R,4S,5R,6R)-3-carbamimidamido-6-{[(2R,3R,4R,5S)-3-{[(2S,3S,4S,5R,6S)-4,5-dihydroxy-6-(hydroxymethyl)-3-(methylamino)oxan-2-yl]oxy}-4-formyl-4-hydroxy-5-methyloxolan-2-yl]oxy}-2,4,5-trihydroxycyclohexyl]guanidine Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N 2-mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 229940097269 Borrelia burgdorferi Drugs 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 108010060123 Conjugate Vaccines Proteins 0.000 description 2
- 229940047650 Haemophilus influenzae Drugs 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 229940072221 IMMUNOGLOBULINS Drugs 0.000 description 2
- 102000004090 Immunoglobulin Isotypes Human genes 0.000 description 2
- 108090000539 Immunoglobulin Isotypes Proteins 0.000 description 2
- 102000018358 Immunoglobulins Human genes 0.000 description 2
- 108060003951 Immunoglobulins Proteins 0.000 description 2
- 210000004698 Lymphocytes Anatomy 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N Tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 210000001541 Thymus Gland Anatomy 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular Effects 0.000 description 2
- 230000001268 conjugating Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 102000037240 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000002609 media Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003278 mimic Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003252 repetitive Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic Effects 0.000 description 2
- ZZDZNJNSVSSOAD-KDEZDQJESA-N (2S)-6-amino-N-[(2S)-2-[(2-amino-2-methylpropanoyl)amino]-3-(4H-imidazol-4-yl)propanoyl]-2-[[(2R)-2-[[(2R)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)C(C)(N)C)C(=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=1C=CC=CC=1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C1C=NC=N1 ZZDZNJNSVSSOAD-KDEZDQJESA-N 0.000 description 1
- RPAMJVCYUGTNKM-UHFFFAOYSA-N 1-hydroxy-3-(2-iodoacetyl)pyrrolidine-2,5-dione Chemical compound ON1C(=O)CC(C(=O)CI)C1=O RPAMJVCYUGTNKM-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-Trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- IBVAQQYNSHJXBV-UHFFFAOYSA-N Adipic acid dihydrazide Chemical compound NNC(=O)CCCCC(=O)NN IBVAQQYNSHJXBV-UHFFFAOYSA-N 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 206010060945 Bacterial infection Diseases 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 102100003729 CD40LG Human genes 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N Cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 206010013023 Diphtheria Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229960002743 Glutamine Drugs 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010018987 Haemorrhage Diseases 0.000 description 1
- 208000002672 Hepatitis B Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N Isoniazid Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010025169 Lyme disease Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- 229940049954 Penicillin Drugs 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M Propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 239000007759 RPMI Media 1640 Substances 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229960005322 Streptomycin Drugs 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 208000001877 Whooping Cough Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 description 1
- 229960000626 benzylpenicillin Drugs 0.000 description 1
- 230000000740 bleeding Effects 0.000 description 1
- 231100000319 bleeding Toxicity 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007330 chocolate agar Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001332 colony forming Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement Effects 0.000 description 1
- 230000000875 corresponding Effects 0.000 description 1
- 210000004748 cultured cells Anatomy 0.000 description 1
- 230000003229 cytophilic Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 230000001809 detectable Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000534 elicitor Effects 0.000 description 1
- 230000037266 fold induction Effects 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000001963 growth media Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 101500002148 human Transforming growth factor beta-2 Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 101700049451 lppL Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000005614 monoclonal antibodies Human genes 0.000 description 1
- 108010045030 monoclonal antibodies Proteins 0.000 description 1
- 229960000060 monoclonal antibodies Drugs 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 201000005702 pertussis Diseases 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000015929 positive regulation of B cell proliferation Effects 0.000 description 1
- 230000003389 potentiating Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000002062 proliferating Effects 0.000 description 1
- 230000001681 protective Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Definitions
- the present invention relates to the use of bacterial lipoproteins in inducing humoral immunity in response to polysaccharide antigens and other T cell-independent antigens.
- TI T cell-independent
- PRP polyribosyl- ribitolphosphate
- Pneumococcal capsular polysaccharides including type III
- Group B creptococcus serocharides and P. aeruginosa capsular polysaccharides (including strain Fisher type 1) .
- FIG. 3 is a series of charts demonstrating that lipo-D costimulates both IgM secretion and proliferation by ⁇ -dex- activated sort-purified B cells in a manner similar to that observed for the non-sorted B cell-enriched population.
- FIG. 4 is a chart demonstrating that lipo-D costimulates IgA class switching to a degree similar to that seen with LPS.
- FIG. 5 is a graph depicting the costimulation of IgM secretion by ⁇ -dex-activated-cells with lipo-OSPA.
- FIG. 6 sets forth the anti-polysaccharide response (Fig. ⁇ a) and the anti-protein response (Fig. 6b) between vaccines based on two different proteins, tetanus toxoid and lipoprotein D.
- the present invention provides methods of inducing and enhancing the immune response to TI antigens by the coadministration of lipoproteins.
- the immune response is the body's production of immunoglobulins, or antibodies, in response to a foreign entity. Inducing the immune response refers to establishing an immune response that did not previously exist whereas enhancing an immune response refers to optimizing or increasing a preexisting immune response.
- the foreign entity of interest in the present invention is the thymus cell (or T cell) -independent antigen or TI antigen.
- the TI antigen can induce an immune response by activating B cells directly without the apparent participation of T cells.
- the thymus dependent antigen (TD) requires T cell help for antibody synthesis.
- Type 1 antigens such as bacterial lipopolysaccharides, may activate B cells "polyclonally, " that is, regardless of the antigen specificity of the B cell.
- Type 2 TI antigen ⁇ are characterized by their linear nature and spaced highly repetitive determinants. Such antigens bind to antigenspecific B cells by cross-linking the Ig receptors on to a charge effect) and both alum and other experimental adjuvants may cause inflammatory responses.
- the present invention addresses these needs by providing a method of inducing the immune response to polysaccharides and other TI antigens by the coadministration of either microbial or synthetic lipoproteins.
- This coadministration includes injection of lipoproteins together with an antigen or a vaccine, or covalently attached to the antigen or the vaccine, as well as injection of the synthetically-derived active moiety of lipoproteins either together with antigen or covalently attached to the antigen.
- the lipoproteins of the present invention also provide a method of enhancing the immune response.
- the lipoprotein of the invention is lipoprotein D.
- FIG. 1 is a graph depicting the over 25-fol ⁇ enhancements in 3 H-TdR incorporation observed with combined ⁇ -dex + lipo-D stimulation, relative to that seen using ⁇ -dex alone.
- FIG. 2 provides two graphs on the induction of Ig secretion by small resting B cells in the absence (Expt. A) or the presence (Expt. B) of ⁇ -dex, showing that lipo-D alone failed to stimulate significant Ig secretion but that the combined action of lipo-D and ⁇ -dex led to an over 10, 000- fold induction in Ig secretion. played key roles in their action, and how lipoprotein-mediated signaling integrated functionally with other B cell stimuli, including mlg-mediated TI-2-like stimuli also present in bacterial cell walls.
- the lipoproteins of the present invention may be either of microbial origin or may be synthetic lipoproteins.
- the microbial lipoproteins are generally components of bacterial cell walls and include, but are not limited to, the distinct -lipoproteins that have been identified in the cell walls of different bacteria. Erdile, L. , et al. , Inf. and Imm. (1993) 61:81.
- the lipoproteins of the current invention may also be derived from the genes encoding them, such as lipoprotein-D from Haemophilus influenzae and lipoprotein-OSPA from Borrelia burgdorferi . Id. and see Son ⁇ et al.. Infect. & Immun. (1995) 63(2) :696.
- the lipoproteins of the present invention also include synthetic lipid moieties, as typified by Pam 3 Cys, that are structurally similar to the amino terminus of bacterial lipoproteins. Klein. B. , et al. , Immunology (1987) 61:29. When these synthetic lipid moieties are conjugated to a small peptide, they can mimic the B cell-activating properties of these molecules. Further, removal of this lipid moiety from bacterial lipoproteins renders them non-functional.
- the lipoproteins of the claimed invention also include fragments or sections thereof that impart the proliferation and Ig secretion actions observed with lipoprotein D. the surface of the B cell, a process known as membrane (m)Ig- mediated signaling.
- cytokines may hamper the treatment of those who need it most: the immunocompromised patients.
- Such patients who lack functional T cells, cannot produce cytokines and thus are at risk for infection by clinically relevant TI antigens such as polysaccharides derived from Haemophilus influenzae type b polyribosyl-ribitol-phosphate (PRP) , S. Pneumonia , Group B Streptococcus, N. men ing i t ide ⁇ , Salmonella, P. aeruginosa mucoexopolysaccharides, and P. aeruginosa (including strain Fisher type 1) .
- PRP polyribosyl-ribitol-phosphate
- S. Pneumonia S. Pneumonia
- Group B Streptococcus N. men ing i t ide ⁇
- Salmonella P. aeruginosa mucoexopolysaccharides
- P. aeruginosa including strain
- Lipoproteins have been previously shown to deliver non- mlg-mediated signals to B cells. Melchers. et al.. 49 J. Exp. Med. (1975) 142:473.
- Prior studies on the B cell activating properties of lipoproteins employed heterogenous populations of lymphoid cells in various stages of in vivo- preactivation and cultured at relatively high cell densities which tend to facilitate interactions of B cells with other cell types. Because these cells were not fractionated according to density and, hence, prior activation state, these studies left unresolved whether lipoproteins acted directly at the level of the resting B cell, whether additional cell types specifically incorporated herein by reference.
- the lipoproteins may be co-administered with the vaccine in any way familiar to those of ordinary skill in the art.
- the lipoproteins may be simply co-injected with the vaccine or bound directly to the vaccine by, for example, the CDAP method mentioned above, although any form of chemical binding is within the scope of this invention.
- the lipoproteins of the claimed invention may be administered by any method familiar to those of ordinary skill in the art, but are preferably administered by intravenous, intramuscular, intranasal, oral, and subcutaneous injections.
- the dosage can be readily determined by those of ordinary skill in the art, but an acceptable range is .01 ⁇ g to 100 ⁇ g per inoculum.
- Secondary booster immunizations may be given at intervals ranging from one week to many months later. Similar approaches can be used in T cell depleted animals or humans.
- typical doses may range from 0.1 to 100 ⁇ g per inoculum and may be given at the same site as the antigen or vaccine, or at a different site of injection.
- protein D is important in enhancing its effectiveness as a carrier molecule, at least in mice and possibly in other species as well.
- protein D is not as effective as lipoprotein D in enhancing anti-polysaccharide responses when injected into mice as a protein-polysaccharide conjugate.
- Example 1 Materials and Methods Mice.
- Female DBA/2 mice were obtained from the National Cancer Institute (Frederick, MD) and were used at 7-10 weeks of age. The experiments were conducted according to the As set forth in the Examples, in contrast to previous studies, neither lipoprotein-D, lipoprotein-OSPA, nor Pam 3 Cys by themselves stimulate significant proliferation or Ig secretion.
- these molecules costimulate striking inductions of Ig secretion and marked enhancements in cellular proliferation in the absence of exogenous cytokines.
- the lipoproteins of the claimed invention may be coadministered with the antigen in any way familiar to those of ordinary skill in the art.
- the lipoproteins may be simply co-injected with the antigen or bound directly to the antigen. Any form of chemical binding, including covalent, is within the scope of this invention.
- a preferred -method of covalent conjugation is set forth in application Serial No. 08/482,661, filed June 7, 1995, which is a continuation-in-part of application Serial No. 08/408,717, filed March 22, 1995, which is a continuation-in-part of application Serial No. 07/124,491, filed September 23, 1993, the so-called "CDAP" conjugation method, the disclosures of which are specifically incorporated herein by reference.
- the invention also encompasses fusion proteins comprised of lipoproteins and the antigen of interest and/or also injection of the DNA from which these fusion proteins were derived.
- the lipoproteins of the claimed invention may be administered with a vaccine, such as the dual conjugate vaccines of application Serial No. 08/468,060, filed June 6, 1995 (a continuation-in-part of application Serial No. 08/402,565, filed March 13, 1995) and the dual conjugate vaccines of application Serial No. 08/444,727, filed May 19, 1995 (a continuation of 08/055,163, filed February 10, 1993), the disclosures of which are were eliminated by treatment with rat anti-Thy-I, anti-CD4, and anti-CD8 monoclonal antibodies, followed by monoclonal mouse anti-rat Ig ⁇ and complement.
- a vaccine such as the dual conjugate vaccines of application Serial No. 08/468,060, filed June 6, 1995 (a continuation-in-part of application Serial No. 08/402,565, filed March 13, 1995) and the dual conjugate vaccines of application Serial No. 08/444,727, filed May 19, 1995 (a continuation of 08/055,163, filed February 10, 1993), the disclosures of which are were eliminated by treatment with
- Cells were fractionated on the basis of their density over discontinuous Percoll gradients (Pharmacia, Piscataway, NJ) consisting of 70, 65, 60, and 50% Percoll solutions (with densities of 1.086, 1.081, 1.074, and 1.062 g/ml, respectively) .
- the high density (small, resting) cells were collected from the 70 to 65% interface and consisted of -90% B cells. Unless otherwise indicated these cells were used in the studies reported herein.
- Highly purified B cells were obtained by electronic cell sorting of membrane (m) IgM+CD3-cells on an EPICS Elite cytometer (Coulter Corp, Hialeah, FL) after staining T- depleted, small, resting spleen cells with FITC-anti-CD3e + PE-anti-IgM antibodies. Sorted cells were immediately reanalyzed and found to be consistently >99% B cells. Functional assays were carried out in either 96- or 24 well flat-bottom Costar plates (Costar, Cambridge, MA) .
- Cultured- cells were incubated at 1 x IO 5 cells/ml in a total volume of 200 ⁇ L (96-well plate) or 1 ml (24-well plate) at 37°C in a humidified atmosphere containing 6% C0 2 .
- Cells were harvested (PHD cell harvester, Cambridge Technology, Watertown, MA) onto glass fiber filters and [ 3 H]TdR incorporation was determined by liquid scintillation spectrometry.
- Ig isotype concentrations were measured by an ELISA assay.
- concentrations of secreted IgM, IgG3, (IgGl, IgG2b, IgG2a) , and IgA in culf re SN Im ulon 2, 96-well flat-bottomed ELISA plates (Dynatech Laboratories, Inc., Alexandria, VA) were coated with unlabelled affinity-purified polyclonal goat anti-mouse IgM, IgG3 , IgG, and IgA antibodies (Southern Biotechnology principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Animal Resources, National Research Council, Department of Health, Education, and Welfare Publ No. (National Institutes of Health) 78-23.
- RPMI 1640 Biofluids, Rockville, MD
- 10% fetal bovine serum (Sigma, St. Louis, MO)
- L-glutamine (2 mM)
- 2-mercaptoethanol 0.05 mM
- penicillin 50 ⁇ g/ml
- streptomycin 50 ⁇ g/ml
- ⁇ -Dex was prepared by conjugation of H ⁇ a /1 (monoclonal mouse IgG2b (b allotype) anti-mouse IgD (a allotype)) to a high molecular weight dextran (2 x IO 6 M.W.) as previously described in Pecanha, L.. et al., J. Immunol. (1991) 146:833. Approximately 9 H ⁇ a /1 antibodies were conjugated to each dextran molecule.
- Pam 3 Cys (S-[2,3- Bis (palmitoyloxy) - (2-RS) -propyl] -N-palmitoyl- (R) -cysteine) was obtained from Boehringer Mannheim Biochemica. A stock solution was prepared by dissolving 1 mg of Pam 3 Cys in 1 ml of 95% ethanol, and stored at -20°C until used.
- Murine rIFN- ⁇ prepared from Chinese hamster ovary cells, was obtained from Genentech (South San Francisco, CA) .
- Murine recombinant IL-1, IL-2, IL-4, and IL-5 were obtained from Dr. Stephanie Vogel (USUHS, 3ethesda, MD) , Dr.
- PE-labelled affinity- purified polyclonal goat anti-mouse IgM antibody was purchased from Southern Biotechnology Associates (Birmingham, AL) .
- Monoclonal rat IgG2b anti-mouse Fc ⁇ RII (2.4G2) was purified from ascites.
- lipoproteins including lipoprotein-D (lipo-D)
- lipoprotein-D lipoprotein-D
- studies used heterogeneous populations of lymphoid cells typically cultured at relatively high cell density (1 x IO 6 cells/ml) .
- the inventors thus tested the effects of lipo-D on a highly-enriched population of small resting B cells cultured at relatively low cell density (1 x IO 5 cells/ml) .
- ⁇ -dex is an in vi tro model for mlg-dependent TI-2 immunity as mediated by bacterial polysaccharides, and stimulates B cell proliferation, but not Ig secretion, in the absence of additional stimuli.
- bacteria express constituents that could deliver both antigen-specific and non-specific stimuli directly to B cells for induction of humoral immunity
- the inventors determined the effects of combined stimulation by optimal and suboptimal concentrations of ⁇ -dex with varying concentrations of lipo-D for B cell mitogenesis, as measured by 3 H-TdR incorporation. Whereas lipo-D by itself was relatively ineffective, it was markedly synergistic with ⁇ -dex for induction of proliferation.
- IgM IgM, IgD, IgG3, IgGl, IgG2b, IgG2a, IgE, and IgA
- Flow cytometric analysis Cells were first incubated for 20 min with 5 ⁇ g/ml final concentration of rat IgG2b anti- Fc ⁇ RII mAb (2.4G2) to prevent cytophilic binding of FITC-rat IgGl anti-mouse IgA mAb which was subsequently added at 10 ⁇ g/ml final concentration for an additional 30 min. All steps were carried out at 4°C.
- Fluorescence analysis was accomplished on a FACScan (Becton Dickinson, Mountain View, CA) using logarithmic amplification. Only viable cells, identified on the basis of their characteristic forward and side scatter profiles and their exclusion of propidium iodide (Sigma) , were analyzed. depleted spleen cells stained with PE-anti-IgM + FITC-anti- CD3. Any residual large, activated B cells were further eliminated on the basis of their characteristic forward scatter profile. As indicated in Fig. 3, lipo-D costimulated both proliferation and IgM secretion by ⁇ -dex-activated sort- purified B cells in a manner similar to that observed for the non-sorted B cell-enriched population. Thus, lipo-D acts directly at the level of the B cell to mediate these effects.
- IgM and IgG3 T cell-independent humoral immune responses to bacteria often show a selective proclivity towards the production of IgM and IgG3.
- This experiment determined the Ig isotypic profile of Ig synthesized in response to lipo-D by ⁇ -dex- activated B cells. As indicated in Table 1, lipo-D induced mostly IgM secretion by ⁇ -dex-activated cells. The remainder of the secreted Ig was IgG ( ⁇ 1%) , mostly IgG3. Thus, Ig isotype secretion in response to costimulation with lipo-D is similar to that obtained in B cells activated with LPS alone.
- Lipo-D-mediated Ig isotype production B cells were stimulated with 5 ⁇ g/ml of lipo-D in combination with 0.3 ng/ml of ⁇ -dex and the concentrations of various Ig isotypes in culture SN were measured 6 days later by ELISA. dex, which by itself was relatively ineffective at stimulating proliferation, strongly costimulated proliferation when combined with 1 ⁇ g/ml of lipo-D. By contrast, up to 30 ⁇ g/ml of unconjugated bivalent anti-IgD antibody failed to costimulate proliferation with lipo-D (data not shown) indicating that multivalent mig crosslinkage was required for this effect. The inventors had previously reported that unconjugated anti-IgD antibody was nevertheless capable of activating B cells as evidenced by its ability to upregulate MHC class II molecule expression and increase B cell size.
- Lipo-D acts directly on the B cell to costimulate proliferation and Ig secretion
- Lipo-D is a relatively poor costimulator of cvtokine-mediated Ig secretion.
- B cells were stimulated in the presence or absence of lipo-D (5 ⁇ g/ml) or ⁇ -dex (3 ng/ml) with or without the indicated cytokines and IgM concentrations in culture SN were measured 6 days later by ELISA.
- Cytokines were added at initiation of culture, except IFN- ⁇ which was added at 24 hours, at the following concentrations: IL-1 (150 U/ml) , 11-2 (150 U/ml), IL-3 (100 U/ml), IL-4 (3,000 U/ml), IL-5 (150 U/ml), GM-CSF (100 U/ml), IFN- ⁇ (10 U/ml) .
- Lipo-D provides key signals for induction of Ig class switching
- Lipo-D by itself is a relatively poor costimulator of cytokine-dependent Ig secretion
- Ig secretion in response to ⁇ -dex activation requires the concomitant action of cytokines.
- IL-4 + IL-5 induce large Ig secretory responses in both ⁇ -dex-activated B cells.
- the inventors recently defined a second cytokine pathway for eliciting Ig secretory response which operates in ⁇ -dex- activated cells.
- IL-3, GM-CSF, and IFN- ⁇ each synergize with IL-I + IL-2 for induction of Ig secretion by ⁇ -dex- activated sort-purified B cells.
- IL-I + IL-2 In B cell-enriched, but not sort-purified, cell cultures, IL-I + IL-2 by itself stimulates Ig secretion that is dependent upon secretion that is dependent upon the presence of AsGm-l + non-B, non-T cells.
- this experiment involved the addition of either IL-4 + IL-5 or IL-I + IL-2 and/or IL-3, GM- CSF, or IFN- ⁇ to lipo-D-stimulated B cell-enriched cultures and the direct comparison of Ig secretion with analogous cultures stimulated with ⁇ -dex.
- IL-4 + IL-5 exhibited some Ig inducing activity in lipo-D-stimulated cells (over 8-fold compared to 1, 600-fold using ⁇ -dex) .
- IL-1 + IL-2 + IL-3 also led to an over 4-fold induction in Ig secretion by lipo-D-activated cells compared to an over 380-fold induction using ⁇ -dex-activated cells.
- lipo-D by itself is a relatively poor costimulator of cytokine-dependent Ig secretion. low, if any, detectable response, it induced a significant response when injected together with lipoprotein D. This demonstrates that lipoprotein D can be used as an adjuvant to enhance responses to polysaccharide antigens.
- mice Groups of 5 DBA/2 mice were injected when DT-Pnl4 in the presence or absence of lipoprotein D. Anti-Pnl4 ELISA were measured 28 days later.
- Lipoprotein D can enhance anti-polysaccharide response in T-cell deficient animals
- mice were injected with 500 ⁇ g - 1.0 mg of an anti-CD4 antibody (GK1.5, obtained from ATCC) to induce T cell depletion.
- GK1.5 an anti-CD4 antibody
- mice were injected with 5.0 ⁇ g of either pneumococcal polysaccharide type 14-lipoprotein D ("PN14-LPD") or PN14 alone.
- IgGl anti- PN14 responses were measured.
- lipoprotein D conjugates stimulated high levels of anti-PN14 response in T cell depleted mice.
- lipo-D provided a key signal for inducing IgA class switching in this system.
- lipo-OSPA lipo-OSPA from Borrelia burgdorferi
- the causative agent of Lyme disease in humans as well as a synthetic lipoprotein consensus structure, Pam 3 Cys.
- lipo-OSPA strongly costimulated IgM secretion by ⁇ -dex-activated-cells.
- Pam 3 Cys also strongly costimulated mitogenesis and Ig secretion.
- lipo-D and in contrast to previous studies, neither lipo-OSPA nor Pam 3 Cys by themselves significantly enhanced either proliferation or Ig secretion by small resting B cells but required coactivation with ⁇ -dex to mediate these affects.
- Lipoprotein D can enhance the anti-polysaccharide response when given together with polysaccharide-protein conjugates
- DT-Pnl4 Diphtheria toxoid pneumococcal polysaccharide was injected at various doses in the, presence or absence of lipoprotein D.
- lipoprotein D induced a 5-10 fold greater anti-polysaccharide response than was seen with DT-Pnl4 alone.
- Figure 6a depicts the anti-polysaccharide response.
- the lipoprotein D conjugate induced a comparable primary anti-PS response to that of the tetanus toxoid conjugate, PRP-TT but induced a much higher (> 10X) secondary anti-PS response than the tetanus toxoid-PS.
- the PRP-LPD conjugate induced a very low anti- lipoprotein D response.
- DTPa.HB vaccine (Diphtheria, tetanus toxoid, acellular pertussis with Hepatitis B) was combined with the conjugates.
- the combination did not diminish the anti-polysaccharide response.
- the conjugates were prepared using the CDAP activation and coupling chemistry (different PS/protein ratios) described below.
- the conjugates were characterized in vi tro for their antigenicity using anti-PS and anti-LPD antibodies and the amount of free PS was determined by immunoprecipitation.
- the immunogenicity of the conjugates was evaluated in a rat model and the protective efficacy of anti-PS antibodies induced in rats was evaluated in infant rats (protection against Hib) or in mice (protection against S. pneumoniae 6B) .
- the Hib PRP and S. pneumoniae polysaccharide 6B and 14 were extracted and purified from inactivated cell cultures.
- the purified material met the WHO and US specifications in Table 4
- Conjugate vaccine with lipoprotein D as a component stimulates anti-polysaccharide response in T cell depleted mice
- lipoprotein D enhance anti-polysaccharide responses in immunocompetent animals, but it also enhances anti-polysaccharide responses in T cell depleted animals. Accordingly, lipoprotein D may be a valuable tool to enhance anti-polysaccharide responses in T cell deficient individuals, such as those suffering from HIV.
- Hib vaccines included either tetanus toxoid (TT) and lipoprotein D (LPD) as the source of T cell epitopes.
- TT tetanus toxoid
- LPD lipoprotein D
- a PRP-TT Hib vaccine was prepared using CNBr activation of the polysaccharide and PRP-TT and PRP-LPD Hib vaccines were prepared using CDAP activation of the polysaccharide.
- Groups of 10 female 5 week old OFA rats were immunized twice subcutaneously 4 weeks apart with 1/4 of a H.D. of the vaccines, and bleedings were taken on day 28, 42, 56, 69 and 83.
- Anti-PRR'P response evaluated by ELISA (coating with tyraminated-PRR'P) .
- a non-parametric method called "Robust” was used for the comparison of the anti-PS titres induced by different preparations.
- HIB 001A44 served as reference.
- Pnl4 is activated with CDAP as above. At 2.5 minutes, one half volume of 0.5 M adipic dihydrazide at pH 8 is added. After one hour, the solution is exhaustively dialyzed into saline.
- Hydrazide content is measured using TNBS, polysaccharide using a resorcinol assay.
- Lipoprotein is coupled to the Pnl4-hydrazide as described by Lees, et al.. Vaccine, 1994, 12, 1160.
- the Pnl4- Hydrazide is iodoacetylated with iodoacetyl N- hydroxysuccinimide (SIA, Sigma) .
- the protein is thiolated with S-Acetylthioacetyl N-hydroxysuccinimide (SATA, Sigma) . Following desalting and concentration using a Centricon 30 device, the two are combined and the pH raised to 7.5 using 1/9 volume of 0.75 M HEPES, 0.5 M hydroxylamine.
- Groups of 10 OFA rats (female, 5-6 weeks old) were injected subcutaneously (200 ⁇ l) with an amount of conjugate corresponding to 2.5 ⁇ g of PS (for PRP) or ranging from 0.1 to 10 ⁇ g of PS (pneumococcal PS 6B or PS 14) .
- the rats were boosted with the same amount of conjugates one month later and a blood sample was collected immediately before and 15 days after the booster for antibody analysis.
- the anti-LPD antibodies were measured by ELISA using protein D as coating antigen.
- Anti-PS antibodies were measured by ELISA using tyraminated PS for coating and, for anti-PS 6B or 14, absorption of anti-CPS antibodies was performed by addition of terms of residual protein, nucleic acid, endotoxin, structural sugars and molecular size distribution.
- Haemophilus influenzae lipoprotein D was expressed in E. coli and purified using conventional column chromatography. The purity of the proteins was above 90% as assessed by different methods (SDS-PAGE, CE,HPLC)
- the activated Hib PRP, S. pneumoniae polysaccharide 6B or S. Pneumoniae polysaccharide 14 were conjugated to lipoprotein D or tetanus toxoid. Two methods for conjugating the polysaccharide to the lipoprotein or tetanus toxoid are disclosed herein. Coupling of LipoD to Pnl4 A. Direct conjugation using CDAP
- Pnl4 is in saline @ 5 mg/ml on ice.
- CDAP @ 100 mg/ml in acetonitrile, 0.2 M TEA, 6 mg/ml lipoprotein D in 10 mM sodium phosphate, 0.2 M NaCl, 0.1% Empigen (a detergent from CalBiochem) pH 7.2, on ice.
- Activation and coupling are performed at 0-4°C.
- CDAP is slowly added to a stirred solution of Pnl4 at a ratio of 0.75 mg CDAP/mg Pnl4.
- the pH is raised to 10 with TEA (usually about 2x the volume of CDAP used) and maintained at pH 10 for a total of 2 minutes with TEA.
- the lipoprotein D is added to the activated Ps, while mixing, at ratio of 2.5 mg protein/mg Pnl4.
- the pH should be in the range of 9-9.5.
- the reaction is quenched by the addition of one quarter volume of 1 M glycine @ pH 8. After an overnight incubation at 4°C, the conjugate is purified by passage over an S500HR (Pharmacia) gel filtration column.
- the high molecular weight conjugate containing protein and polysaccharide, is pooled and filtered through a 0.2 micron filter. Protein is determined using the Lowery assay, polysaccharide using a resorcinol assay. Full protection was observed with anti-PS 6B-LPD conjugates in a passive mouse protection test.
- CPS CPS to the serum (1 mg/ml for anti-PS 14 and 5 mg/ml for anti- PS 6B) .
- the detection of specific antibodies was made using an anti-rat conjugate labelled to peroxidase.
- a reference serum was used and the titers were calculated in arbitrary units using the 4-parameter methods.
- mice (outbred 0F1, 6 weeks old, female mice) were injected intraperitoneally with 10 3 CFU of S. pneumoniae bacteria type 6B, 24 hours after passive immunization with serum (100 ⁇ l of 1.5 dilution) containing anti-PS 6B antibodies.
- the control groups were injected with the serum of nonimmunized animals or animal ⁇ immunized with PS 14 conjugates. The number of deaths in each group was recorded during the next 18 days.
- anti-PS response (anti-PRP, anti-PS6B) is higher (at least 10 times) when LPD is used instead of TT as the protein.
- Antibodies induced by PRP-LPD conjugates are at least equivalent or .even better than antibodies induced by PRP-TT conjugates (at equivalent titer) in a passive protection model in infant rat.
- Table 7 :
- the bacteremia was determined after 24 hrs.
- mice with ⁇ 10 CFU/100 ⁇ l of blood were considered protected.
- Controls have 10 3 - IO 6 CFU ⁇ l of blood.
- Table 6 Evaluation of PRP conjugates obtained by the CDAP technology using TT or LPD as carrier.
- Non immunized rats have mean titers of 0. 1 1 and 0 04 for anti-PS in Exp. I and II respectively .
- Table 8 Evaluation of PS-6B conjugates obtained by the CDAP technology using TT or LPD as carrier.
- lipidation rats were injected with 0.1 to 30 ⁇ g of a conjugate of lipoprotein D (Lipo D) , protein D, or tetanus toxoid conjugated to pneumococcal polysaccharide 6B.
- Lipo D, Protein D, and pneumococcal polysaccharide 6B were prepared according to the methods as discussed above at pages 6 and 20-21. Tetanus toxoid is easily obtained from many sources known to those ordinarily skilled in the art.
- Conjugates were prepared as discussed above at pages 20-22.
- the protein D conjugates were prepared using the same methodology as that set forth for lipoprotein D conjugates .
- Anti-polysaccharide responses were measured by ELISA 28 days after initial injection of the conjugate and 28 days after a booster injection. As set forth in Table 11, anti- polysaccharide responses were significantly higher in mice injected with the Lipo D-conjugate as compared to those injected with the protein D conjugate.
- mice 5 weeks old female OFA mice were injected IP with 100 ⁇ l of serum diluted 5 fold and challenged 24 hours with 100 ⁇ l of Pn 6B strain (6/6B/52) passaged twice in mice. The mortality was recorded up to 18 days after challenge.
- a method of inducing an immune response to polysaccharides or other T cell-independent antigen in an individual comprising: administering the antigen, and coadministering a lipoprotein.
- the antigen is a polysaccharide derived from a bacteria selected from a group consisting of Haemophilus influenzae type b, S. pneumonia , Group B Streptococcus, N. meningi tidis, Salmonella, and P. aeruginosa ucoexopolysaccharides .
- a method of enhancing responses to polysaccharides or other T cell-independent antigens comprising: administering the antigen, and coadministering a lipoprotein.
- the antigen is a polysaccharide derived from a bacteria selected from a group consisting of Haemophilus influenzae type b, S. pneumonia , Group B Streptococcus, N. meningi tidis , Salmonella , and P . aeruginosa mucoexopolysaccharides .
- a vaccine comprising a clinically relevant polysaccharide covalently attached to lipoprotein D.
- polysaccharide is derived from a bacteria selected from a group consisting of Table 11
Abstract
The present invention provides a method of inducing or enhancing an immune response to polysaccharides or other T cell-independent antigen by the coadministration of the antigen with bacterial lipoproteins (including covalent attachment of the antigen and lipoproteins). In a preferred embodiment, the lipoprotein of the invention is lipoprotein D.
Description
INDUCTION AND ENHANCEMENT OF THE IMMUNE RESPONSE TO POLYSACCHARIDES WITH BACTERIAL LIPOPROTEINS
GOVERNMENT INTEREST
The invention described herein may be manufactured, licensed and used for governmental purposes without the payment of any royalties to us thereon.
CROSS REFERENCE TO RELATED APPLICATION
This application is a continuation-in-part of application Serial No. 08/472,640, filed June 7, 1995, which is a continuation-in-part of application serial No. 08/422,830, filed April 17, 1995.
FIELD OF THE INVENTION
The present invention relates to the use of bacterial lipoproteins in inducing humoral immunity in response to polysaccharide antigens and other T cell-independent antigens.
BACKGROUND
The cellular basis for induction of T cell-independent (TI) humoral immunity to bacterial organisms and their antigenic constituents is largely unknown, thus hampering efforts to develop sufficient defenses against bacterial infection. This poses serious problems, given the prevalence and significance of TI antigens from bacterial organisms such as Haemophilus influenzae type b polyribosyl- ribitolphosphate (PRP) , Pneumococcal capsular polysaccharides (including type III) , Group B creptococcus serocharides, and P. aeruginosa capsular polysaccharides (including strain Fisher type 1) .
This dearth of knowledge aside, immunologists do know that immunity requires the stimulation of B cell proliferation as well as Ig secretion. In related patent application Serial 08/315,492, filed September 30, 1994, the inventors previously demonstrated that B cells activated by αδ-dex, a construct that mimics the repetitive nature of the
FIG. 3 is a series of charts demonstrating that lipo-D costimulates both IgM secretion and proliferation by αδ-dex- activated sort-purified B cells in a manner similar to that observed for the non-sorted B cell-enriched population.
FIG. 4 is a chart demonstrating that lipo-D costimulates IgA class switching to a degree similar to that seen with LPS.
FIG. 5 is a graph depicting the costimulation of IgM secretion by αδ-dex-activated-cells with lipo-OSPA.
FIG. 6 sets forth the anti-polysaccharide response (Fig. βa) and the anti-protein response (Fig. 6b) between vaccines based on two different proteins, tetanus toxoid and lipoprotein D.
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides methods of inducing and enhancing the immune response to TI antigens by the coadministration of lipoproteins. As used herein, the immune response is the body's production of immunoglobulins, or antibodies, in response to a foreign entity. Inducing the immune response refers to establishing an immune response that did not previously exist whereas enhancing an immune response refers to optimizing or increasing a preexisting immune response.
As noted above, the foreign entity of interest in the present invention is the thymus cell (or T cell) -independent antigen or TI antigen. The TI antigen can induce an immune response by activating B cells directly without the apparent participation of T cells. Conversely, the thymus dependent antigen (TD) requires T cell help for antibody synthesis.
There are two known classes of TI antigens. Type 1 antigens, such as bacterial lipopolysaccharides, may activate B cells "polyclonally, " that is, regardless of the antigen specificity of the B cell. Type 2 TI antigenε are characterized by their linear nature and spaced highly repetitive determinants. Such antigens bind to antigenspecific B cells by cross-linking the Ig receptors on
to a charge effect) and both alum and other experimental adjuvants may cause inflammatory responses.
Thus, there is a need in the art for methods to induce immunoglobulins either to antigens that by themselves may not be able to induce adequate amounts of T cell help or cytokine-derived help, as for example, polysaccharides, as well as a need in the art to enhance the immune response in individuals that lack the ability to recruit this type of help. There is also a need in the art to enhance the immune responses to those antigens where currently available adjuvants are ineffective.
SUMMARY OF THE INVENTION The present invention addresses these needs by providing a method of inducing the immune response to polysaccharides and other TI antigens by the coadministration of either microbial or synthetic lipoproteins. This coadministration includes injection of lipoproteins together with an antigen or a vaccine, or covalently attached to the antigen or the vaccine, as well as injection of the synthetically-derived active moiety of lipoproteins either together with antigen or covalently attached to the antigen. The lipoproteins of the present invention also provide a method of enhancing the immune response. In a preferred embodiment, the lipoprotein of the invention is lipoprotein D.
BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 is a graph depicting the over 25-folά enhancements in 3H-TdR incorporation observed with combined αδ-dex + lipo-D stimulation, relative to that seen using αδ-dex alone. FIG. 2 provides two graphs on the induction of Ig secretion by small resting B cells in the absence (Expt. A) or the presence (Expt. B) of αδ-dex, showing that lipo-D alone failed to stimulate significant Ig secretion but that the combined action of lipo-D and αδ-dex led to an over 10, 000- fold induction in Ig secretion.
played key roles in their action, and how lipoprotein-mediated signaling integrated functionally with other B cell stimuli, including mlg-mediated TI-2-like stimuli also present in bacterial cell walls.
In contrast to these other studies, the work that led to this invention used highly-enriched and sort-purified resting murine B cells. With this specific population of B cells, the data indicate that lipoproteins must act in concert with other stimuli to induce strong proliferative and Ig secretory responses. These data are consistent with a recent study using >98% pure, small resting human B cells, in which synthetic lipopeptide significantly enhanced proliferation and Ig secretion only when acting in concert with anti-CD40 antibody.
The lipoproteins of the present invention may be either of microbial origin or may be synthetic lipoproteins. The microbial lipoproteins are generally components of bacterial cell walls and include, but are not limited to, the distinct -lipoproteins that have been identified in the cell walls of different bacteria. Erdile, L. , et al. , Inf. and Imm. (1993) 61:81. The lipoproteins of the current invention may also be derived from the genes encoding them, such as lipoprotein-D from Haemophilus influenzae and lipoprotein-OSPA from Borrelia burgdorferi . Id. and see Sonσ et al.. Infect. & Immun. (1995) 63(2) :696.
The lipoproteins of the present invention also include synthetic lipid moieties, as typified by Pam3Cys, that are structurally similar to the amino terminus of bacterial lipoproteins. Klein. B. , et al. , Immunology (1987) 61:29. When these synthetic lipid moieties are conjugated to a small peptide, they can mimic the B cell-activating properties of these molecules. Further, removal of this lipid moiety from bacterial lipoproteins renders them non-functional.
The lipoproteins of the claimed invention also include fragments or sections thereof that impart the proliferation and Ig secretion actions observed with lipoprotein D.
the surface of the B cell, a process known as membrane (m)Ig- mediated signaling.
Much has been learned about mlg-mediated signaling in response to TI antigens based on a polyclonal in vi tro model developed by the inventors. The inventors synthesized dextran-conjugated anti-IgD antibodies (αδ-dex) in order to simulate the repeating epitope nature of polysaccharides. αδ- Dex cross-links mlg in a multivalent fashion and induces potent and sustained B cell signaling. αδ-Dex, which stimulates proliferation by small resting B cells, fails to induce Ig secretion in the absence of exogenous cytokines, and recent studies show that TI antigens similarly cannot induce Ig secretion in the absence of such cytokines.
The requirement for cytokines may hamper the treatment of those who need it most: the immunocompromised patients. Such patients, who lack functional T cells, cannot produce cytokines and thus are at risk for infection by clinically relevant TI antigens such as polysaccharides derived from Haemophilus influenzae type b polyribosyl-ribitol-phosphate (PRP) , S. Pneumonia , Group B Streptococcus, N. men ing i t ide ε , Salmonella, P. aeruginosa mucoexopolysaccharides, and P. aeruginosa (including strain Fisher type 1) . The coadministration of lipoprotein of this invention, however, results in B cell proliferation and Ig secretion even in the absence of cytokines, as set forth in detail below.
Lipoproteins have been previously shown to deliver non- mlg-mediated signals to B cells. Melchers. et al.. 49 J. Exp. Med. (1975) 142:473. Prior studies on the B cell activating properties of lipoproteins, however, employed heterogenous populations of lymphoid cells in various stages of in vivo- preactivation and cultured at relatively high cell densities which tend to facilitate interactions of B cells with other cell types. Because these cells were not fractionated according to density and, hence, prior activation state, these studies left unresolved whether lipoproteins acted directly at the level of the resting B cell, whether additional cell types
specifically incorporated herein by reference. As with the antigen, the lipoproteins may be co-administered with the vaccine in any way familiar to those of ordinary skill in the art. As above, the lipoproteins may be simply co-injected with the vaccine or bound directly to the vaccine by, for example, the CDAP method mentioned above, although any form of chemical binding is within the scope of this invention.
When used as a vaccine, the lipoproteins of the claimed invention may be administered by any method familiar to those of ordinary skill in the art, but are preferably administered by intravenous, intramuscular, intranasal, oral, and subcutaneous injections. The dosage can be readily determined by those of ordinary skill in the art, but an acceptable range is .01 μg to 100 μg per inoculum. Secondary booster immunizations may be given at intervals ranging from one week to many months later. Similar approaches can be used in T cell depleted animals or humans.
For use of lipoprotein D as an adjuvant, typical doses may range from 0.1 to 100 μg per inoculum and may be given at the same site as the antigen or vaccine, or at a different site of injection.
Additional studies have shown that lipidation of protein D is important in enhancing its effectiveness as a carrier molecule, at least in mice and possibly in other species as well. Thus, protein D is not as effective as lipoprotein D in enhancing anti-polysaccharide responses when injected into mice as a protein-polysaccharide conjugate.
The invention will be further clarified by the following examples, which are intended to be purely exemplary of the invention.
Example 1 Materials and Methods Mice. Female DBA/2 mice were obtained from the National Cancer Institute (Frederick, MD) and were used at 7-10 weeks of age. The experiments were conducted according to the
As set forth in the Examples, in contrast to previous studies, neither lipoprotein-D, lipoprotein-OSPA, nor Pam3Cys by themselves stimulate significant proliferation or Ig secretion. However, in combination with Tl-like, multivalent antigen receptor cross-linking, these molecules costimulate striking inductions of Ig secretion and marked enhancements in cellular proliferation in the absence of exogenous cytokines. Moreover, these act directly at the level of the B cell without a requirement for recruitment of non-B cell types. These data suggest an additional, novel pathway for induction of specific, T cell-independent humoral immunity in response to bacterial challenge.
The lipoproteins of the claimed invention may be coadministered with the antigen in any way familiar to those of ordinary skill in the art. For example, the lipoproteins may be simply co-injected with the antigen or bound directly to the antigen. Any form of chemical binding, including covalent, is within the scope of this invention. A preferred -method of covalent conjugation is set forth in application Serial No. 08/482,661, filed June 7, 1995, which is a continuation-in-part of application Serial No. 08/408,717, filed March 22, 1995, which is a continuation-in-part of application Serial No. 07/124,491, filed September 23, 1993, the so-called "CDAP" conjugation method, the disclosures of which are specifically incorporated herein by reference. The invention also encompasses fusion proteins comprised of lipoproteins and the antigen of interest and/or also injection of the DNA from which these fusion proteins were derived.
In addition to an antigen, the lipoproteins of the claimed invention may be administered with a vaccine, such as the dual conjugate vaccines of application Serial No. 08/468,060, filed June 6, 1995 (a continuation-in-part of application Serial No. 08/402,565, filed March 13, 1995) and the dual conjugate vaccines of application Serial No. 08/444,727, filed May 19, 1995 (a continuation of 08/055,163, filed February 10, 1993), the disclosures of which are
were eliminated by treatment with rat anti-Thy-I, anti-CD4, and anti-CD8 monoclonal antibodies, followed by monoclonal mouse anti-rat Igκ and complement. Cells were fractionated on the basis of their density over discontinuous Percoll gradients (Pharmacia, Piscataway, NJ) consisting of 70, 65, 60, and 50% Percoll solutions (with densities of 1.086, 1.081, 1.074, and 1.062 g/ml, respectively) . The high density (small, resting) cells were collected from the 70 to 65% interface and consisted of -90% B cells. Unless otherwise indicated these cells were used in the studies reported herein. Highly purified B cells were obtained by electronic cell sorting of membrane (m) IgM+CD3-cells on an EPICS Elite cytometer (Coulter Corp, Hialeah, FL) after staining T- depleted, small, resting spleen cells with FITC-anti-CD3e + PE-anti-IgM antibodies. Sorted cells were immediately reanalyzed and found to be consistently >99% B cells. Functional assays were carried out in either 96- or 24 well flat-bottom Costar plates (Costar, Cambridge, MA) . Cultured- cells were incubated at 1 x IO5 cells/ml in a total volume of 200 μL (96-well plate) or 1 ml (24-well plate) at 37°C in a humidified atmosphere containing 6% C02.
Measurement of DNA synthesis. DNA synthesis was determined by 3H-TdR uptake (2μCi/well; 6.7 Ci/nmol; lmCi = 37 GBq; ICN, Irvine, CA) over a 4 hr period. Cells were harvested (PHD cell harvester, Cambridge Technology, Watertown, MA) onto glass fiber filters and [3H]TdR incorporation was determined by liquid scintillation spectrometry.
Quantitation of secreted Iσ isotype concentrations in culture SN. Ig isotype concentrations were measured by an ELISA assay. For determination of concentrations of secreted IgM, IgG3, (IgGl, IgG2b, IgG2a) , and IgA in culf re SN, Im ulon 2, 96-well flat-bottomed ELISA plates (Dynatech Laboratories, Inc., Alexandria, VA) were coated with unlabelled affinity-purified polyclonal goat anti-mouse IgM, IgG3 , IgG, and IgA antibodies (Southern Biotechnology
principles set forth in the Guide for the Care and Use of Laboratory Animals, Institute of Animal Resources, National Research Council, Department of Health, Education, and Welfare Publ No. (National Institutes of Health) 78-23.
Culture medium. RPMI 1640 (Biofluids, Rockville, MD) supplemented with 10% fetal bovine serum (Sigma, St. Louis, MO), L-glutamine (2 mM) , 2-mercaptoethanol (0.05 mM) , penicillin (50 μg/ml) and streptomycin (50 μg/ml) were used for culturing cells.
Reagents . αδ-Dex was prepared by conjugation of Hδa/1 (monoclonal mouse IgG2b (b allotype) anti-mouse IgD (a allotype)) to a high molecular weight dextran (2 x IO6 M.W.) as previously described in Pecanha, L.. et al., J. Immunol. (1991) 146:833. Approximately 9 Hδa/1 antibodies were conjugated to each dextran molecule. Pam3Cys (S-[2,3- Bis (palmitoyloxy) - (2-RS) -propyl] -N-palmitoyl- (R) -cysteine) was obtained from Boehringer Mannheim Biochemica. A stock solution was prepared by dissolving 1 mg of Pam3Cys in 1 ml of 95% ethanol, and stored at -20°C until used. Murine rIFN-γ prepared from Chinese hamster ovary cells, was obtained from Genentech (South San Francisco, CA) . Murine recombinant IL-1, IL-2, IL-4, and IL-5 were obtained from Dr. Stephanie Vogel (USUHS, 3ethesda, MD) , Dr. Maurice Gately (Hoffman-La Roche, Nutley, NJ) , Dr. Alan Levine (Searle, St. Louis, MO) , and Dr. Richard Hodes (NIH, Bethesda, MD) , respectively. Recombinant human TGF-β2 was obtained from Wendy Waegell (Celtrix Pharmaceuticals, Santa Clara, CA) . Recombinant murine IL-3 and GM-CSF were purchased from Pharmingen. FITC-anti-CD3e mAb (2C11) and FITC-rat IgGl anti-mouse IgA mAb were purchased from Pharmingen (San Diego, CA) . PE-labelled affinity- purified polyclonal goat anti-mouse IgM antibody was purchased from Southern Biotechnology Associates (Birmingham, AL) . Monoclonal rat IgG2b anti-mouse FcγRII (2.4G2) was purified from ascites.
Preparation and culture of B cells. Enriched populations of B cells were obtained from spleen cells from which T cells
Example 2
Lipo-D by itself is an ineffective mitogen for resting B cells but is markedly synergistic with mlg signaling
Previous reports indicated that lipoproteins, including lipoprotein-D (lipo-D) , by themselves stimulated substantial B cell proliferation and Ig secretion. These studies used heterogeneous populations of lymphoid cells typically cultured at relatively high cell density (1 x IO6 cells/ml) . Thus, they left unanswered whether additional cell types and the state of B cell activation were important parameters in mediating these lipoprotein effects. The inventors thus tested the effects of lipo-D on a highly-enriched population of small resting B cells cultured at relatively low cell density (1 x IO5 cells/ml) . In contrast to the findings of previous reports, resting B cells proliferated weakly or not at all in response to lipo-D, added from 0.02 to 5 μg/ml (Fig. 1). Concentrations of lipo-D up to 40 μg/ml were also ineffective (data not shown) . By contrast, B cells proliferated vigorously in response to LPS (data not shown) .
The inventors had previously demonstrated that αδ-dex is an in vi tro model for mlg-dependent TI-2 immunity as mediated by bacterial polysaccharides, and stimulates B cell proliferation, but not Ig secretion, in the absence of additional stimuli. To test the hypothesis that bacteria express constituents that could deliver both antigen-specific and non-specific stimuli directly to B cells for induction of humoral immunity, the inventors determined the effects of combined stimulation by optimal and suboptimal concentrations of αδ-dex with varying concentrations of lipo-D for B cell mitogenesis, as measured by 3H-TdR incorporation. Whereas lipo-D by itself was relatively ineffective, it was markedly synergistic with αδ-dex for induction of proliferation. Over 25-fold enhancements in 3H-TdR incorporacion were observed with combined αδ-dex + lipo-D stimulation, relative to that seen using αδ-dex alone (Fig. 1). As little as 0.3 ng/ml of αδ-
Associates, Birmingham, AL) , respectively. Plates were then washed, blocked with FBS-containing buffer, and incubated with various dilutions of culture SN and standards. After washing, plates were incubated with alkaline phosphatase-conjugated affinity-purified, polyclonal goat anti-mouse IgM, IgG3, IgGl, IgG2b, IgG2a, and IgA antibodies (Southern Biotechnology Associates) as indicated, washed again, and a fluorescent product was generated by cleavage of exogenous 4-methyl umbilliferyl phosphate (Sigma) by the plate-bound alkaline phosphatase-conjugated antibodies. For determination of IgE concentrations, a similar procedure was followed except that plates were coated with monoclonal rat IgG2a anti-mouse IgE (clone EM95) [purified from ascites, obtained from Dr. Fred Finkelman, USUHS, Bethesda, MD] , followed by samples and standards, then affinity-purified polyclonal rabbit anti-mouse IgE (obtained from Dr. Ildy Katona, USUHS, Bethesda, MD) , then alkaline phosphatase-conjugated affinity-purified polyclonal goat anti-rabbit IgG (Southern Biotechnology Associates) . Fluorescence was quantitated on a 3M FluoroFAST 96 fluorometer (Mountainview, CA) and fluorescence units were converted to Ig concentrations by interpolation from standard curves that were determined with known concentrations of purified myeloma Ig. Each assay system showed no significant cross-reactivity or interference from other Ig isotypes (IgM, IgD, IgG3, IgGl, IgG2b, IgG2a, IgE, and IgA) found in the culture supematants. Flow cytometric analysis. Cells were first incubated for 20 min with 5 μg/ml final concentration of rat IgG2b anti- FcγRII mAb (2.4G2) to prevent cytophilic binding of FITC-rat IgGl anti-mouse IgA mAb which was subsequently added at 10 μg/ml final concentration for an additional 30 min. All steps were carried out at 4°C. Fluorescence analysis was accomplished on a FACScan (Becton Dickinson, Mountain View, CA) using logarithmic amplification. Only viable cells, identified on the basis of their characteristic forward and side scatter profiles and their exclusion of propidium iodide (Sigma) , were analyzed.
depleted spleen cells stained with PE-anti-IgM + FITC-anti- CD3. Any residual large, activated B cells were further eliminated on the basis of their characteristic forward scatter profile. As indicated in Fig. 3, lipo-D costimulated both proliferation and IgM secretion by αδ-dex-activated sort- purified B cells in a manner similar to that observed for the non-sorted B cell-enriched population. Thus, lipo-D acts directly at the level of the B cell to mediate these effects.
Example 5
Activation of αδ-dex-stimulated B cells with lipo-D leads to predominant secretion of IgM with smaller amounts of mostly IgG3
T cell-independent humoral immune responses to bacteria often show a selective proclivity towards the production of IgM and IgG3. This experiment determined the Ig isotypic profile of Ig synthesized in response to lipo-D by αδ-dex- activated B cells. As indicated in Table 1, lipo-D induced mostly IgM secretion by αδ-dex-activated cells. The remainder of the secreted Ig was IgG (<1%) , mostly IgG3. Thus, Ig isotype secretion in response to costimulation with lipo-D is similar to that obtained in B cells activated with LPS alone.
Table 1 Ig Secretion (ng/ml)
IgM IgG3 IgGl IgG2b IgG2a IgE IgA Lipo-D+αδ-dex 31,900 255 12 13 <6 <1 <6
Lipo-D-mediated Ig isotype production. B cells were stimulated with 5 μg/ml of lipo-D in combination with 0.3 ng/ml of αδ-dex and the concentrations of various Ig isotypes in culture SN were measured 6 days later by ELISA.
dex, which by itself was relatively ineffective at stimulating proliferation, strongly costimulated proliferation when combined with 1 μg/ml of lipo-D. By contrast, up to 30 μg/ml of unconjugated bivalent anti-IgD antibody failed to costimulate proliferation with lipo-D (data not shown) indicating that multivalent mig crosslinkage was required for this effect. The inventors had previously reported that unconjugated anti-IgD antibody was nevertheless capable of activating B cells as evidenced by its ability to upregulate MHC class II molecule expression and increase B cell size.
Example 3
Combined stimulation with lipo-D and αδ-dex leads to a striking induction of Ig secretion in the absence of exogenous cytokines
The next experiment determined whether lipo-D induced Ig secretion by small resting B cells in the presence or absence of αδ-dex. Lipo-D alone (0.2-5 μg/ml, Fig. 2, Expt A; 5-20 μg/ml, Fig. 2, Expt B) failed to stimulate significant Ig secretion. As reported previously, αδ-dex by itself was also an ineffective inducer of Ig synthesis by resting B cells. However, the combined action of lipo-D and αδ-dex led to an over 10, 000-fold induction in Ig secretion in the absence of exogenous cytokines (Fig. 2) . 5 μg/ml of lipo-D and 0.3 ng/ml of αδ-dex were found to be optimal for costimulation of Ig secretion. Higher and lower concentrations of lipo-D and αδ- dex were relatively inhibitory and ineffective, respectively.
Example 4
Lipo-D acts directly on the B cell to costimulate proliferation and Ig secretion
To determine whether lipo-D acts directly on the resting B cell to costimulate proliferation and Ig secretion in combination with αδ-dex, the inventors obtained a highly purified population of resting B cells (>99% mIgM+CD3-) through the method of electronic cell sorting of small T cell-
Table 2
IBM secretion (nq/ml)
Medium Lipo-D αδ-dex
Medium <6 420 72
IL-4+IL-5 565 3,625 117,000
IL-l+IL-2 <6 410 5,875
IL-3 <6 1,600 350
GM-CSF 7 600 435
IFN-γ <6 470 130
IL-l,2+IL-3 12 1,950 27,500
IL-1,2+GM-CSF <6 450 18,437
IL-l,2+IFN-γ 7 290 16,875
Lipo-D is a relatively poor costimulator of cvtokine-mediated Ig secretion. B cells were stimulated in the presence or absence of lipo-D (5 μg/ml) or αδ-dex (3 ng/ml) with or without the indicated cytokines and IgM concentrations in culture SN were measured 6 days later by ELISA. Cytokines were added at initiation of culture, except IFN-γ which was added at 24 hours, at the following concentrations: IL-1 (150 U/ml) , 11-2 (150 U/ml), IL-3 (100 U/ml), IL-4 (3,000 U/ml), IL-5 (150 U/ml), GM-CSF (100 U/ml), IFN-γ (10 U/ml) .
Example 7
Lipo-D provides key signals for induction of Ig class switching
In related application Serial No. 08/400,322, filed March 8, 1995, the inventors recently established an in vi tro model for induction of high-rate IgA class switching which required the combined action of αδ-dex with either LPS or CD40L in the presence of IL-4, IL-5, and the IgA switch factor, TGF-β. In this system all stimuli were required in order to obtain over 10% mIgA+ cells, as assessed by flow cytometric analysis. In this experiment, the inventors determined whether lipo-D could replace LPS for costimulation of IgA class switching. In the absence of TGF-β, few if any mlgA* cells were detected, four days after initiation of culture (Fig. 5) . Removal from culture of LPS led to a drop in %mIgA+ cells to <.2% as previously reported (data not shown) . However, replacement of LPS with lipo-D led to a
Example 6
Lipo-D by itself is a relatively poor costimulator of cytokine-dependent Ig secretion
Ig secretion in response to αδ-dex activation requires the concomitant action of cytokines. Thus, IL-4 + IL-5 induce large Ig secretory responses in both αδ-dex-activated B cells. The inventors recently defined a second cytokine pathway for eliciting Ig secretory response which operates in αδ-dex- activated cells. Thus, IL-3, GM-CSF, and IFN-γ each synergize with IL-I + IL-2 for induction of Ig secretion by αδ-dex- activated sort-purified B cells. In B cell-enriched, but not sort-purified, cell cultures, IL-I + IL-2 by itself stimulates Ig secretion that is dependent upon secretion that is dependent upon the presence of AsGm-l+ non-B, non-T cells. Thus, to determine the ability of lipo-D to costimulate cytokine-dependent Ig secretion, this experiment involved the addition of either IL-4 + IL-5 or IL-I + IL-2 and/or IL-3, GM- CSF, or IFN-γ to lipo-D-stimulated B cell-enriched cultures and the direct comparison of Ig secretion with analogous cultures stimulated with αδ-dex. As indicated in Table 2, αδ- dex strongly costimulated Ig secretion in response to both cytokine pathways described above. By contrast, lipo-D was a relatively poor costimulator of these Ig secretory responses. Specifically, IL-4 + IL-5 exhibited some Ig inducing activity in lipo-D-stimulated cells (over 8-fold compared to 1, 600-fold using αδ-dex) . In addition the combination of IL-1 + IL-2 + IL-3 also led to an over 4-fold induction in Ig secretion by lipo-D-activated cells compared to an over 380-fold induction using αδ-dex-activated cells. Thus, lipo-D by itself is a relatively poor costimulator of cytokine-dependent Ig secretion.
low, if any, detectable response, it induced a significant response when injected together with lipoprotein D. This demonstrates that lipoprotein D can be used as an adjuvant to enhance responses to polysaccharide antigens.
Table 3
Enhancement of anti-polysaccharide response by coinjection with lipoprotein D
IgG Anti-Pnl4 titer dose (ug) injected lipo D dav 28
DT-Pnl4 .1 - 1,318
.01 - 20
DT-Pnl4 .1 + 10,240
.01 + 498
Groups of 5 DBA/2 mice were injected when DT-Pnl4 in the presence or absence of lipoprotein D. Anti-Pnl4 ELISA were measured 28 days later.
Example 10
Lipoprotein D can enhance anti-polysaccharide response in T-cell deficient animals
Mice were injected with 500 μg - 1.0 mg of an anti-CD4 antibody (GK1.5, obtained from ATCC) to induce T cell depletion. One day later, the mice were injected with 5.0 μg of either pneumococcal polysaccharide type 14-lipoprotein D ("PN14-LPD") or PN14 alone. Fourteen days later, IgGl anti- PN14 responses were measured. As set forth below in Table 4, lipoprotein D conjugates stimulated high levels of anti-PN14 response in T cell depleted mice.
restoration in the IgA class switching response to over 8% mIgA+ cells. Thus, lipo-D provided a key signal for inducing IgA class switching in this system.
Example 8
Costimulation of proliferation and Ig secretion by lipo-D in αδ-dex-activated B cells appears to be a general property of bacterial lipoproteins
A series of analogous experiments were performed using another recombinant lipoprotein, lipo-OSPA from Borrelia burgdorferi , the causative agent of Lyme disease in humans as as well as a synthetic lipoprotein consensus structure, Pam3Cys. As indicated in Figure 5, lipo-OSPA strongly costimulated IgM secretion by αδ-dex-activated-cells. Further, Pam3Cys also strongly costimulated mitogenesis and Ig secretion. As with lipo-D, and in contrast to previous studies, neither lipo-OSPA nor Pam3Cys by themselves significantly enhanced either proliferation or Ig secretion by small resting B cells but required coactivation with αδ-dex to mediate these affects. Thus, these data suggest that bacterial lipoproteins in general, which deliver non-specific signals to B cells, must act in concert with specific B cell activating signals such as that mediated by mig cross-linking (multivalent antigen binding) in order to induce a strong, humoral immune response, without a requirement for recruiting ion-B cells .
Example 9
Lipoprotein D can enhance the anti-polysaccharide response when given together with polysaccharide-protein conjugates
Diphtheria toxoid pneumococcal polysaccharide (DT-Pnl4) was injected at various doses in the, presence or absence of lipoprotein D. The addition of lipoprotein D induced a 5-10 fold greater anti-polysaccharide response than was seen with DT-Pnl4 alone. Furthermore, while 0.01 μg of DT-Pnl4 elicited
Figure 6a depicts the anti-polysaccharide response. The lipoprotein D conjugate, the PRP-LPD, induced a comparable primary anti-PS response to that of the tetanus toxoid conjugate, PRP-TT but induced a much higher (> 10X) secondary anti-PS response than the tetanus toxoid-PS. As set forth in Figure 6b, the PRP-LPD conjugate induced a very low anti- lipoprotein D response.
The experiment also suggested that the anti- polysaccharide responses are similar 14 and 28 days after booster. At day 69, (41 days after the booster), the response began to decrease for some conjugates, including the lipoprotein D conjugate.
In addition, to assess the effect of combined vaccines, a
DTPa.HB vaccine (Diphtheria, tetanus toxoid, acellular pertussis with Hepatitis B) was combined with the conjugates.
The combination did not diminish the anti-polysaccharide response.
Example 12
The Antigenicity and Immunogenicity of Lipoprotein D Constructs
In this experiment, we evaluated the effect of the conjugation of lipoprotein D conjugated to Hib PRP and S. pneumoniae PS 14 and 6B.
The conjugates were prepared using the CDAP activation and coupling chemistry (different PS/protein ratios) described below. The conjugates were characterized in vi tro for their antigenicity using anti-PS and anti-LPD antibodies and the amount of free PS was determined by immunoprecipitation. The immunogenicity of the conjugates was evaluated in a rat model and the protective efficacy of anti-PS antibodies induced in rats was evaluated in infant rats (protection against Hib) or in mice (protection against S. pneumoniae 6B) . Materials and Methods
The Hib PRP and S. pneumoniae polysaccharide 6B and 14 were extracted and purified from inactivated cell cultures. The purified material met the WHO and US specifications in
Table 4
Conjugate vaccine with lipoprotein D as a component stimulates anti-polysaccharide response in T cell depleted mice
Antigen Anti-CD4 IgGl anti-PN14
(μg/mouse) dl4
PN14-LPD (5.0) + 5,834
PN14 (5.0) + < 10
Thus, not only does lipoprotein D enhance anti-polysaccharide responses in immunocompetent animals, but it also enhances anti-polysaccharide responses in T cell depleted animals. Accordingly, lipoprotein D may be a valuable tool to enhance anti-polysaccharide responses in T cell deficient individuals, such as those suffering from HIV.
Example 11
To assess the effect of the protein on the anti- polysaccharide response, different vaccines based on Haemophilus influenzae type b polyribosyl-ribitol-phosphate (PRP) were prepared. These "Hib vaccines" included either tetanus toxoid (TT) and lipoprotein D (LPD) as the source of T cell epitopes. A PRP-TT Hib vaccine was prepared using CNBr activation of the polysaccharide and PRP-TT and PRP-LPD Hib vaccines were prepared using CDAP activation of the polysaccharide.
Groups of 10 female 5 week old OFA rats were immunized twice subcutaneously 4 weeks apart with 1/4 of a H.D. of the vaccines, and bleedings were taken on day 28, 42, 56, 69 and 83.
Anti-PRR'P response evaluated by ELISA (coating with tyraminated-PRR'P) . A non-parametric method called "Robust" was used for the comparison of the anti-PS titres induced by different preparations. HIB 001A44 served as reference.
B. Coupling via a spacer
Pnl4 is activated with CDAP as above. At 2.5 minutes, one half volume of 0.5 M adipic dihydrazide at pH 8 is added. After one hour, the solution is exhaustively dialyzed into saline.
Hydrazide content is measured using TNBS, polysaccharide using a resorcinol assay.
Lipoprotein is coupled to the Pnl4-hydrazide as described by Lees, et al.. Vaccine, 1994, 12, 1160. In brief, the Pnl4- Hydrazide is iodoacetylated with iodoacetyl N- hydroxysuccinimide (SIA, Sigma) . The protein is thiolated with S-Acetylthioacetyl N-hydroxysuccinimide (SATA, Sigma) . Following desalting and concentration using a Centricon 30 device, the two are combined and the pH raised to 7.5 using 1/9 volume of 0.75 M HEPES, 0.5 M hydroxylamine. After an overnight reaction at 4°C, the reaction is quenched with mercaptoethanol @ 0.2 mNM for one hour, followed by iodoacetamide @ 10 mM for 10 minutes. The conjugate is purified as described above. Those skilled in the art will recognize that other methods of conjugating protein to polysaccharide may also be practiced.
Experimental Results
1. Jjnmunoσeπiσitv of conjugates in rats
Groups of 10 OFA rats (female, 5-6 weeks old) were injected subcutaneously (200 μl) with an amount of conjugate corresponding to 2.5 μg of PS (for PRP) or ranging from 0.1 to 10 μg of PS (pneumococcal PS 6B or PS 14) . The rats were boosted with the same amount of conjugates one month later and a blood sample was collected immediately before and 15 days after the booster for antibody analysis. The anti-LPD antibodies were measured by ELISA using protein D as coating antigen. Anti-PS antibodies were measured by ELISA using tyraminated PS for coating and, for anti-PS 6B or 14, absorption of anti-CPS antibodies was performed by addition of
terms of residual protein, nucleic acid, endotoxin, structural sugars and molecular size distribution.
Haemophilus influenzae lipoprotein D was expressed in E. coli and purified using conventional column chromatography. The purity of the proteins was above 90% as assessed by different methods (SDS-PAGE, CE,HPLC)
The activated Hib PRP, S. pneumoniae polysaccharide 6B or S. Pneumoniae polysaccharide 14 were conjugated to lipoprotein D or tetanus toxoid. Two methods for conjugating the polysaccharide to the lipoprotein or tetanus toxoid are disclosed herein. Coupling of LipoD to Pnl4 A. Direct conjugation using CDAP
Pnl4 is in saline @ 5 mg/ml on ice. CDAP @ 100 mg/ml in acetonitrile, 0.2 M TEA, 6 mg/ml lipoprotein D in 10 mM sodium phosphate, 0.2 M NaCl, 0.1% Empigen (a detergent from CalBiochem) pH 7.2, on ice.
Activation and coupling are performed at 0-4°C. CDAP is slowly added to a stirred solution of Pnl4 at a ratio of 0.75 mg CDAP/mg Pnl4. At 30 seconds, the pH is raised to 10 with TEA (usually about 2x the volume of CDAP used) and maintained at pH 10 for a total of 2 minutes with TEA.
After a total of 2.5 minutes, the lipoprotein D is added to the activated Ps, while mixing, at ratio of 2.5 mg protein/mg Pnl4. The pH should be in the range of 9-9.5.
After one hour, the reaction is quenched by the addition of one quarter volume of 1 M glycine @ pH 8. After an overnight incubation at 4°C, the conjugate is purified by passage over an S500HR (Pharmacia) gel filtration column.
The high molecular weight conjugate, containing protein and polysaccharide, is pooled and filtered through a 0.2 micron filter. Protein is determined using the Lowery assay, polysaccharide using a resorcinol assay.
Full protection was observed with anti-PS 6B-LPD conjugates in a passive mouse protection test.
Conclusion
These results demonstrate that LPD is a superior protein as compared to TT for the different capsular PS tested (PRP, PS 6B)
CPS to the serum (1 mg/ml for anti-PS 14 and 5 mg/ml for anti- PS 6B) . The detection of specific antibodies was made using an anti-rat conjugate labelled to peroxidase. For all the ELISA's, a reference serum was used and the titers were calculated in arbitrary units using the 4-parameter methods.
2. Passive protection experiments a) Protection of infant rats against Hib challenge
Infant OFA rats (4-5 days) were injected intra¬ peritoneally (IP) with 100 μl of serum dilutions (in PBS) containing anti-PRP antibodies. Twenty-four hours later, the rats were challenged by the IP route with about 5 x IO4 colony forming units (CFU) of log phase Hib, strain Eagan. After 24 hours, the rats were killed and a blood sample was drawn from each rat. The bacteremia was measured by plating serial dilutions of the blood on chocolate agar and counting the colonies one day later. Rats with less than 10 CFU/100 μl of blood were considered protected. b) Protecting of mice against a lethal challenge bv S. pneumoniae 6B
Groups of 10 mice (outbred 0F1, 6 weeks old, female mice) were injected intraperitoneally with 103 CFU of S. pneumoniae bacteria type 6B, 24 hours after passive immunization with serum (100 μl of 1.5 dilution) containing anti-PS 6B antibodies. The control groups were injected with the serum of nonimmunized animals or animalε immunized with PS 14 conjugates. The number of deaths in each group was recorded during the next 18 days.
The anti-PS response (anti-PRP, anti-PS6B) is higher (at least 10 times) when LPD is used instead of TT as the protein. Antibodies induced by PRP-LPD conjugates are at least equivalent or .even better than antibodies induced by PRP-TT conjugates (at equivalent titer) in a passive protection model in infant rat.
Table 7:
Passive protection in infant rats challenged with Hib by serum from rats immunized with LPD-PRP conjugates
Serum from rats Protection against bacteremia immunized with with
5 lμg/m 0.2 μg/ml 1 μg/ml
NaCl (control) ~ 0/9
TT-PRP 8/9 0/10 0/10
LPD-PRP 003 9/9 4/10 0/8
LPD-PRP 004 10/10 4/8 0/10
Groups of 10 OFA rats (5 days old) were injected IP with 100 μl of serum and challenged 24 hrs later IP with 5.104 CFU/rat (Eagan strain).
The bacteremia was determined after 24 hrs.
Mice with <10 CFU/100 μl of blood were considered protected.
Controls have 103 - IO6 CFU μl of blood.
Table 6: Evaluation of PRP conjugates obtained by the CDAP technology using TT or LPD as carrier.
Non immunized rats have mean titers of 0. 1 1 and 0 04 for anti-PS in Exp. I and II respectively.
Table 8: Evaluation of PS-6B conjugates obtained by the CDAP technology using TT or LPD as carrier.
Conjugates Dose Antibodies at day 42 (rat)
(γ) α-PS (γ/ml)
Exp. I
PS 6B-TT 1 0.1 97
1 16
10 21
2 0.1 140
1 110
30 30
Exp. II
PS6B-LPD
001 0.1 2839
1 1671
10 597
002 0.1 2941
1 1831
10 1125
Exp. Ill
PS 68-LPD
002 0.1 2027
1 272
10 2747
Example 13
To assess the effect of lipidation, rats were injected with 0.1 to 30 μg of a conjugate of lipoprotein D (Lipo D) , protein D, or tetanus toxoid conjugated to pneumococcal polysaccharide 6B. Lipo D, Protein D, and pneumococcal polysaccharide 6B were prepared according to the methods as discussed above at pages 6 and 20-21. Tetanus toxoid is easily obtained from many sources known to those ordinarily skilled in the art. Conjugates were prepared as discussed above at pages 20-22. The protein D conjugates were prepared using the same methodology as that set forth for lipoprotein D conjugates .
Anti-polysaccharide responses were measured by ELISA 28 days after initial injection of the conjugate and 28 days after a booster injection. As set forth in Table 11, anti- polysaccharide responses were significantly higher in mice injected with the Lipo D-conjugate as compared to those injected with the protein D conjugate.
Other embodiments of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with a true scope and spirit of the invention being indicated by the following claims.
Table 10:
Passive protection in mice challenged with S. pneumonaie type 6B by serum from mice immunized with LPD-PS 6B conjugates
Serum from rats N° of surviving mice at day immunized with
10 15 18
NaCl (control) 5/10 4/10 3/10 rat anti-PS 6B 7/10 6/10 6/10 rat anti-PS 6B-LPD 10/10 10/10 10/10 002
rabbit anti-PS 14- 7/10* 3/10 3/10 KLH
*several mice are sick
5 weeks old female OFA mice were injected IP with 100 μl of serum diluted 5 fold and challenged 24 hours with 100 μl of Pn 6B strain (6/6B/52) passaged twice in mice. The mortality was recorded up to 18 days after challenge.
We claim:
1. A method of inducing an immune response to polysaccharides or other T cell-independent antigen in an individual, comprising: administering the antigen, and coadministering a lipoprotein.
2. The method of claim 1 wherein the lipoprotein is derived from a microorganism.
3. The method of claim 2 wherein the lipoprotein is lipoprotein D.
4. The method of claim 1 wherein the lipoprotein is a synthetic lipoprotein.
5. The method of claim 1 wherein the antigen is a polysaccharide derived from a bacteria selected from a group consisting of Haemophilus influenzae type b, S. pneumonia , Group B Streptococcus, N. meningi tidis, Salmonella, and P. aeruginosa ucoexopolysaccharides .
6. A method of enhancing responses to polysaccharides or other T cell-independent antigens, comprising: administering the antigen, and coadministering a lipoprotein.
7. The method of claim 6, wherein the lipoprotein is derived from a microorganism.
8. The method of claim 6 wherein the lipoprotein is lipoprotein D.
9. The method of claim 6 wherein the lipoprotein is a synthetic lipoprotein.
10. The method of claim 6 wherein the antigen is a polysaccharide derived from a bacteria selected from a group consisting of Haemophilus influenzae type b, S. pneumonia , Group B Streptococcus, N. meningi tidis , Salmonella , and P . aeruginosa mucoexopolysaccharides .
11. A vaccine comprising a clinically relevant polysaccharide covalently attached to lipoprotein D.
12. The vaccine of claim 11 wherein the polysaccharide is derived from a bacteria selected from a group consisting of
Table 11
Immunogenicity of PS-6B Conjugates Obtained by the CDAP Technology Using TT, LPD or
Protein D as the Protein Carrier
Conjugates Dose (μg) Antibody Titer (day 42) anti-PS (μg/ml)
Exp. I
PS 6B-TT
001 0.1 97
1 16
10 21
0002 0.1 140
1 110
30 30
Exp. II
PS 6B-LPD
001 0.1 2839
1 1671
10 597
0002 0.1 2941
1 1831
10 1125
Exp- UI
PS 6B-LPD 0002 0.1 2027 1 272 10 2747
PS 6B-PD 001 0.1 49 1 5 10 4
Claims
Haemophilus influenzae type b, S. pneumonia, Group B Streptococcus, N. meningi tidis, Salmonella, and P . aeruginosa mucoexopolysaccharides .
13. A method for making the vaccine of claim 11 wherein the lipoprotein D is directly covalently attached to the polysaccharide.
14. The method of claim 13 wherein the covalent attachment is via CDAP activation of the polysaccharide.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ306316A NZ306316A (en) | 1995-04-17 | 1996-04-16 | use of lipoprotein and a type 2T independent antigen to induce an immune response to the antigen |
EP96911776A EP0824360A1 (en) | 1995-04-17 | 1996-04-16 | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins |
AU54856/96A AU716806B2 (en) | 1995-04-17 | 1996-04-16 | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins |
JP8531844A JPH11508225A (en) | 1995-04-17 | 1996-04-16 | Induction and enhancement of immune responses to polysaccharides using bacterial lipoproteins |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42283095A | 1995-04-17 | 1995-04-17 | |
US08/422,830 | 1995-04-17 | ||
US47264095A | 1995-06-07 | 1995-06-07 | |
US08/472,640 | 1995-06-07 | ||
US56834295A | 1995-12-06 | 1995-12-06 | |
US08/568,342 | 1995-12-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996032963A1 WO1996032963A1 (en) | 1996-10-24 |
WO1996032963A9 true WO1996032963A9 (en) | 1997-04-03 |
Family
ID=27411382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/005226 WO1996032963A1 (en) | 1995-04-17 | 1996-04-16 | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0824360A1 (en) |
JP (1) | JPH11508225A (en) |
KR (1) | KR19990007858A (en) |
AU (1) | AU716806B2 (en) |
CA (1) | CA2218385A1 (en) |
NZ (1) | NZ306316A (en) |
WO (1) | WO1996032963A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3005499A (en) * | 1998-03-16 | 1999-10-11 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Induction and enhancement of the immune response to type-2 cell-independent antigens conjugated to lipid or lipid-containing moieties |
GB9909077D0 (en) * | 1999-04-20 | 1999-06-16 | Smithkline Beecham Biolog | Novel compositions |
BR0009163A (en) * | 1999-03-19 | 2001-12-26 | Smithkline Beecham Biolog | Vaccine |
AU8640501A (en) * | 2000-07-31 | 2002-02-13 | Univ Yale | Innate immune system-directed vaccines |
FR2816060A1 (en) * | 2000-10-27 | 2002-05-03 | Pf Medicament | METHOD FOR IDENTIFYING NEW MOXULES BINDING TO THE LOX RECEPTOR AND USE OF SUCH MOLECULES |
EP3115060A1 (en) | 2008-04-18 | 2017-01-11 | VaxInnate Corporation | Deletion mutants of flagellin and methods of use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0606921B1 (en) * | 1989-03-09 | 2000-08-02 | American Cyanamid Company | Method of isolating haemophilus influenzae protein E |
EP0672684A1 (en) * | 1990-05-31 | 1995-09-20 | Meija Seika Kabushiki Kaisha, Ltd. | Novel megakaryocyte colony stimulating factor and production thereof |
SE466259B (en) * | 1990-05-31 | 1992-01-20 | Arne Forsgren | PROTEIN D - AN IGD BINDING PROTEIN FROM HAEMOPHILUS INFLUENZAE, AND THE USE OF THIS FOR ANALYSIS, VACCINES AND PURPOSE |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
GB9224584D0 (en) * | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
AU678613B2 (en) * | 1993-09-22 | 1997-06-05 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs |
-
1996
- 1996-04-16 JP JP8531844A patent/JPH11508225A/en active Pending
- 1996-04-16 WO PCT/US1996/005226 patent/WO1996032963A1/en not_active Application Discontinuation
- 1996-04-16 NZ NZ306316A patent/NZ306316A/en unknown
- 1996-04-16 EP EP96911776A patent/EP0824360A1/en not_active Withdrawn
- 1996-04-16 AU AU54856/96A patent/AU716806B2/en not_active Ceased
- 1996-04-16 CA CA002218385A patent/CA2218385A1/en not_active Abandoned
- 1996-04-16 KR KR1019970707381A patent/KR19990007858A/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100290632B1 (en) | Immunogenic antigen conjugates and synthetic peptide carriers and vaccines containing them | |
US8198424B2 (en) | Use of flagellin in the immunotherapy of Yersinia pestis | |
Cui et al. | A novel tetrameric gp3501–470 as a potential Epstein–Barr virus vaccine | |
US9260509B2 (en) | Flagellin fusion proteins and use thereof to induce immune responses against Pseudomonas aeruginosa | |
Snapper et al. | Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion | |
MXPA02003788A (en) | Modified plant viruses and methods of use thereof. | |
Snapper et al. | IFN-γis a potent inducer of Ig secretion by sort-purified murine B cella activated through the mlg, but not the CD40, signaling pathway | |
EP1737481A2 (en) | Peptides of il1 beta and tnf alpha and method of treatment using same | |
JP4024298B2 (en) | Therapeutics and autoimmune diseases | |
Pérez‐Melgosa et al. | Carrier‐mediated enhancement of cognate T cell help: the basis for enhanced immunogenicity of meningococcal outer membrane protein polysaccharide conjugate vaccine | |
AU716806B2 (en) | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins | |
US5932427A (en) | In vitro assay system for identifying compositions useful for stimulating B cells | |
WO1996032963A9 (en) | Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins | |
JPH04506666A (en) | LFA-3 as a vaccine adjuvant | |
US20040005321A1 (en) | Use of anti-ceacam antibodies for stimulating b cells in the production of monoclonal antibodies or in immunotheraphy | |
US5824310A (en) | Lipopplysaccharide conjugate vaccines | |
JP2000502995A (en) | Compositions and methods for stimulating antibody release by B lymphocytes | |
US20150225478A1 (en) | Immunogenic and Prophylactic Compositions, Methods of Making Same, and Methods for Treating and Preventing TNF-Mediated Disease | |
WO1999047168A2 (en) | Induction and enhancement of the immune response to type-2 t cell-independent antigens conjugated to lipid or lipid-containing moieties | |
Skokos et al. | Increased Immunogenicity of Mast Cell-Associated Antigens | |
Dagan | Biological activities of the tetrapeptide tuftsin: Receptor sites and immunogenic function | |
AU3777700A (en) | Induction and enhancement of the immune response to type 2 T cell-independent antigens conjugated to lipid or lipid-containing moieties in immunocompromised hosts |